Impact of Diabetes-Related Metabolic Derangements on Clinical Outcomes in Hospitalized Patients With Chronic Kidney Disease

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

• Ages 18 years and older
• All sexes
• No healthy volunteers
• Adult, Older adult

Study population: A) Inclusion criteria: * Age ≥18 years. * Known CKD (baseline eGFR <60 mL/min/1.73 m² for ≥3 months) OR documented CKD stage 3-5 by prior records. * Hospitalized for any medical reason. * Consent provided. B) Exclusion criteria: * Acute single episode of reversible AKI with previously normal renal function (no established CKD). * Admission for palliative care /expected survival <24 hours. * Pregnancy. C) Patient groups (for analysis): Diabetes status: * Diabetic CKD (known diagnosis or on antidiabetic therapy prior to admission). * Non-diabetic CKD. D) Subgroups / Diabetic patient group: Metabolic derangement categories 1. Acute hyperglycemia * Diabetic ketoacidosis (DKA) /hyperosmolar hyperglycemic state (HHS) * Patients without DKA or HHS 2. Hypoglycemia * Hypoglycemia: any blood glucose <70 mg/dL (and severe <40 mg/dL). * Without Hypoglycemia episodes 3. Metabolic acidosis arterial or venous HCO₃- <20 mmol/L or pH <7.35 with anion gap >12 as appropriate.

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

About this study

Conditions

Diabetic Chronic Kidney Disease Patients

Being tested

Primary aim 1. To assess the frequency of diabetes mellitus among hospitalized CKD patients. 2. To evaluate the frequency and types of metabolic abnormalities (e.g., hypoglycemia, diabetic ketoacidosi

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

• Primary aim 1. To assess the frequency of diabetes mellitus among hospitalized CKD patients. 2. To evaluate the frequency and types of metabolic abnormalities (e.g., hypoglycemia, diabetic ketoacidosiBehavioural

  Primary aim

  1. To assess the frequency of diabetes mellitus among hospitalized CKD patients.
  2. To evaluate the frequency and types of metabolic abnormalities (e.g., hypoglycemia, diabetic ketoacidosis/ hyperosmolar states, metabolic acidosis, dyslipidemia, electrolyte imbalance) in diabetic CKD patients.

  Secondary aim

  1. To evaluate the association between diabetes and diabetes-related metabolic derangements in-hospital adverse outcomes (major cardiovascular events, ICU admission, length of stay, infection rate, need for dialysis and mortality) among hospitalized patients with CKD.

What is being measured

The primary outcome is the main question the study is designed to answer.

1. In-Hospital Mortality

   Patient death from any cause occurring during the hospitalization period

   Measured: From admission until hospital discharge, assessed over a 6-month study enrollment period.

2. New Requirement for In-Hospital Renal Replacement Therapy

   Initiation of dialysis in a patient who was not receiving renal replacement therapy at the time of hospital admission

   Measured: From admission until hospital discharge, assessed over a 6-month study enrollment period.

3. Incidence of a Major In-Hospital Cardiovascular Composite Event

   A composite outcome defined as the first occurrence of any of the following during the hospitalization: myocardial infarction, stroke, or new-onset heart failure requiring inotropic support or mechanical ventilation

   Measured: From admission until hospital discharge, assessed over a 6-month study enrollment period.

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

1. First posted21 Jan 2026
2. Study start1 Jan 2026 (estimated)
3. Primary completion30 Jun 2026 (estimated)
4. Study completion31 Aug 2026 (estimated)

Resources

• Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
• Other trials for Diabetic Chronic Kidney Disease PatientsStudies of the same condition, open and under way.
• More trials run by Sohag UniversityThe sponsor's other registered studies.
• What the trial phases meanHow a treatment moves from first tests in people to approval.

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.